Can a diabetes drug protect the heart after a massive attack?

NCT ID NCT06174753

Recruiting now Disease control Sponsor: Ottawa Heart Institute Research Corporation Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether dapagliflozin, a diabetes drug, can limit heart muscle damage in people having a major heart attack (STEMI). Participants receive either the drug or a placebo for 7 days, and heart damage is measured with an MRI. The goal is to see if this drug can improve recovery and reduce future heart problems.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Dapagliflozin (a diabetes drug that may protect the heart)
What this could lead to: If it works, this could show that dapagliflozin reduces heart muscle damage after a heart attack, potentially improving recovery and lowering future heart risks.
What could go wrong: This is a relatively small phase 3 trial (256 people) focused on a specific type of heart attack. The drug may not reduce damage as hoped, and side effects like dehydration or infections are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYOCARDIAL INFARCTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

myocardial infarction ST-elevation myocardial infarction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYOCARDIAL INFARCTION ST ELEVATION MYOCARDIAL INFARCTION

Contacts and locations

Locations

University of Ottawa Heart Institute
RECRUITING

Ottawa, Ontario, K1Y 4W7, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.